226 results about "Cell lymphoma" patented technology

The invention is applicable to the technical field of clinical medicine, provides a clinical multi-modal cancer drug response prediction method based on feature reconstruction, constructs a clinical multi-modal model for drug response prediction of diffuse large B-cell lymphoma, and aims to predict the drug response of diffuse large B-cell lymphoma by integrating gene sequencing and clinical multi-modal data. And accurate drug reaction prediction is realized. The model adopts an end-to-end multi-stage processing flow: firstly, extracting gene features through TransP-Net, and processing multi-modal clinical data by using a clinical information encoder; then, pseudo-gene features are generated through a clinical-genome filling module to deal with the data missing problem; and finally, multi-modal deep fusion is realized through a clinical information decoder, and a prediction result is output. According to the method, data characteristics and working processes in a real clinical environment are fully considered, two conditions of complete gene data and missing gene data can be processed at the same time, and the method has a good clinical transformation prospect and application value.

The invention discloses a diffuse large B-cell lymphoma segmentation system based on deep learning, and the system comprises a data collection module which is used for collecting PET and CT images of a patient; the double-branch encoder module is used for processing PET and CT images respectively; the cross-modal feature cross fusion module is used for extracting positioning clues from the CT anatomical features by taking the PET metabolic features as queries; taking CT structure characteristics as query, and screening PET high-metabolism regions; the global-attention suppression module is used for extracting global context features, performing down-sampling, remodeling input features into a low-dimensional matrix, then performing self-attention calculation, generating a sparse weight matrix for the input features based on a full connection layer, and then performing sparse attention calculation; and finally, fusing the two attention calculation results and outputting enhanced features. And the multi-scale jump connection module is used for fusing the encoder features and the decoder features and recovering spatial details.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

The invention relates to the technical field of biomedicine, in particular to a molecular target for treating recurrent refractory diffuse large B-cell lymphoma and application of the molecular target. According to the invention, a molecular target CSNK1E for treating recurrent refractory diffuse large B-cell lymphoma is excavated; compared with existing traditional targets of other drugs for recurrent lymphoma, the CSNK1E has a remarkable expression difference in the recurrent DLBCL, and it is indicated that the CSNK1E possibly has more remarkable advantages in treatment of the recurrent DLBCL.

The invention relates to the technical field of biological medicine detection, and discloses tsRNA for predicting, diagnosing or monitoring diffuse large B-cell lymphoma, a kit and application of the tsRNA. The marker comprises one or more of six tsRNAs including tsRNA-Leu-CAG, tsRNA-Pro-CG, tsRNA-Gln-CTG, tsRNA-Cys-GCA, tsRNA-Leu-AAG, tsRNA-Lys-CTT and the like, and the nucleotide sequence of the marker is as shown in SEQ ID NO. 1-6; the nucleotide sequence of the marker is as shown in SEQ ID NO. By detecting the change of the expression level of tsRNA in peripheral blood serum, early diagnosis, dynamic monitoring of treatment response and prognosis evaluation of DLBCL can be realized.

The invention discloses a prognosis evaluation method and system for diffuse large B-cell lymphoma. According to the method, firstly, a gene module closely related to lipid metabolism is screened from DLBCL transcriptome data through weighted gene co-expression network analysis (WGCNA), and then eight key prognosis genes including FNDC1, IL22RA2, C15orf48, OMD, MFAP2, BC017398, CXCL6 and TNFAIP6 are identified from the module by adopting multi-step regression analysis (single factor Cox, LASSO and multi-factor Cox). A risk scoring model is constructed based on the expression levels and regression coefficients of the genes, and DLBCL patients can be divided into a high-risk group and a low-risk group with significant survival differences. The risk score and the clinical pathological factors are further integrated to construct a column graph, and individualized survival probability prediction can be achieved. The invention further provides a corresponding prognosis evaluation system, electronic equipment and a storage medium. An independent data set verifies that the prognosis model has excellent prediction performance and clinical practical value.

The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and / or CD20 positive cells and can be used to treat CD19 and / or CD20 positive B-cell lymphoma, leukemia and other diseases.

The invention discloses an application of NF-kappa B and IRF4 in prognosis evaluation of diffuse large B-cell lymphoma, relates to the technical field of disease prognosis and molecular biology, provides a marker for prognosis evaluation of diffuse large B-cell lymphoma, and relates to the application of NF-kappa B and IRF4 in prognosis evaluation of diffuse large B-cell lymphoma. The invention relates to application of a substance for detecting the marker in claim 1 in preparation of a product for prognosis evaluation of diffuse large B-cell lymphoma, and provides a medicine for treating diffuse large B-cell lymphoma. By detecting the marker, the malignancy degree of the DLBCL can be more accurately analyzed, a reliable prognosis evaluation basis is provided for clinicians, and accurate prognosis evaluation is carried out; through targeting NF-kappa B and MUM1 dual-blocking therapeutic drugs, the prognosis of patients is improved, the life quality and the survival rate of the patients are improved, and novel therapeutic drugs are developed; a new breakthrough is brought to diagnosis, treatment and prognosis evaluation of the DLBCL, and potential clinical application value is achieved.

Disclosed herein are synthetic nanoparticles, pharmaceutical compositions, kits, or methods for treating and / or preventing cancer. In some embodiments, the synthetic nanoparticles and / or pharmaceutical compositions comprises a pH sensitive liposome, an apolipoprotein, and andrographolide or derivative thereof. In some embodiments, the synthetic nanoparticles are delivered to a subject for treatment of cancer. In some embodiments, the cancer is T-cell lymphoma or B-cell lymphoma.

The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.

The application provides use of a compound A or a pharmaceutically acceptable salt thereof as a Bruton's tyrosine kinase (BTK) inhibitor in preparation of a drug for treating a BTK-related tumor disease. In vitro and in vivo test results show that the compound A has good inhibitory activity on BTK kinase, good inhibitory activity on human B-cell lymphoma cells with high BTK expression, and good in vivo anti-tumor activity. In addition, the compound A has good pharmacokinetic properties and metabolic stability, and can be used for developing a drug preparation for treating a BTK-related tumor disease, and has important clinical application value.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

The present disclosure relates generally to mutations in T cell lymphoma, and methods of use of the mutations in T cell therapy.

Provided herein are methods for monitoring, identifying, evaluating circulating tumor DNA (ctDNA) for treating a subject or monitoring a subject having cancer, and related methods and uses thereof. In some embodiments, the disease or disorder is relapsed or refractory B-cell lymphoma (BCL).

The invention belongs to the technical field of medicines, and particularly relates to application of dioscin combined with chidamide in diffuse large B-cell lymphoma. Specifically, research finds that the dioscin can significantly inhibit DLBCL cell proliferation and induce cell cycle arrest and apoptosis by up-regulating PINK1 / Parkin mediated mitochondrial autophagy and enhancing H3K27 acetylation mediated epigenetic regulation. When the chidamide and the dioscin are combined for use, a synergistic effect can be generated, and by further increasing the H3K27ac level, the cell apoptosis induction effect is enhanced, and the in-vivo and in-vitro anti-tumor activity on DLBCL is remarkably improved. The invention provides a novel and efficient DLBCL combined treatment scheme, and provides a new pharmaceutical composition and theoretical support for clinical diagnosis and treatment of DLBCL, so that the application has good practical application value.

This disclosure provides a method for treating lymphoma, the method comprising administering a bispecific CD20xCD3 antibody to a patient in need, wherein the patient is selected based on an improvement in the level of circulating tumor (ct) DNA. In some embodiments, this disclosure provides a method for identifying lymphoma patients who may respond well to a therapy comprising a bispecific CD20xCD3 antibody.

The application discloses an index combination for identifying diffuse large B-cell lymphoma and application thereof. The index combination is composed of gender, age and eight oligosaccharide chains, namely NGA2F, NG2FB, NG1A2F-1, NG1A2F-2, NA2F, NA2FB, NA3Fb and NA4Fb. The application also provides a prediction model, a prediction system, a computer readable storage medium and a kit constructed based on the index combination. Experimental results show that the prediction model has a sensitivity of 88.06%, a specificity of 92.98% and an AUC of 0.949 in identifying diffuse large B-cell lymphoma in a verification set. The application realizes, for the first time, non-invasive, rapid and high-accuracy identification of diffuse large B-cell lymphoma based on blood oligosaccharide chains combined with clinical indexes, and provides a brand-new tool for auxiliary differential diagnosis of patients with lymph node enlargement.

The invention relates to the technical field of biological medicines, in particular to a polypeptide targeting B cell lymphoma cells, a targeting effect conjugate and application of the polypeptide and the targeting effect conjugate. Wherein the peptide chain length of the polypeptide targeting the B-cell lymphoma cells is 12 amino acids, and the polypeptide is selectively and specifically combined with the B-cell lymphoma cells. The targeting effect conjugate is formed by connecting polypeptide and pro-apoptotic peptide through a connecting peptide. The pro-apoptotic peptide can induce programmed death of target cells by destroying a mitochondrial membrane structure. The molecular weight of the polypeptide is small, the chemical synthesis process is simple, convenient and efficient, high consistency between different batches of products can be ensured in the synthesis process, and a guarantee is provided for subsequent quality control. The small molecular structure is also convenient for sequence optimization and terminal modification, can create extremely favorable conditions for subsequent structure-function relationship research and pharmaceutical development work, and is helpful for accelerating the research and development process of novel therapeutic drugs.

The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Top1i) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.

This invention relates to the field of molecular diagnostics, specifically providing a diagnostic kit for the combined detection of DLBCL based on plasma exosomal miRNAs. This invention provides two or more peripheral blood exosomes used as diagnostic biomarkers for diffuse large B-cell lymphoma (DLBCL). Based on these DLBCL diagnostic biomarkers, this invention also provides a non-invasive, highly reproducible, and highly specific plasma exosomal miRNA diagnostic kit for the early diagnosis and follow-up monitoring of DLBCL. The plasma exosomal miRNA diagnostic kit provided by this invention is of great significance in the early diagnosis, genotyping, relapse monitoring, and efficacy evaluation of DLBCL.

The application discloses Lactobacillus reuteri and application thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, and relates to the technical field of biological medicine. The application provides application of Lactobacillus reuteri and / or a metabolite thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, wherein the Lactobacillus reuteri is Lactobacillus reuteri (HG001). Limosilactobacillus reuteri The Lactobacillus reuteri is separated from feces of healthy people and used for preparation of the medicine for treating diffuse large B-cell lymphoma, and it is found that the Lactobacillus reuteri is confirmed as a probiotic strain for enhancing the chemotherapy effect of diffuse large B-cell lymphoma and can improve side effects caused by cyclophosphamide treatment of diffuse large B-cell lymphoma; and the Lactobacillus reuteri and the cyclophosphamide have a synergistic effect in treatment of diffuse large B-cell lymphoma.

The embodiment of the present application discloses a genotype classification method for diffuse large B-cell lymphoma, a computer device, and a computer-readable storage medium. The method includes the following steps: testing a sample according to a preset specific gene set to obtain variation detection data; preprocessing the variation detection data to obtain variation information; generating an initial feature matrix based on the variation information, screening the initial feature matrix to obtain a feature matrix, and the feature matrix is ​​used to characterize the gene variation contained in the specific gene set in the corresponding sample; obtaining a first genotype label and an important feature set, constructing a data set based on the feature matrix, the first genotype label, and the important feature set, and training a classification model; obtaining a second genotype label output by the classification model, and determining a genotype classification report based on the second genotype label. Therefore, the present application can reduce the cost of testing, can effectively predict the patient's genotype, and has a high clinical application value.

Described are the compounds, compositions and methods of treating a disease or disorder characterized by aberrant B-cell lymphoma 6 (BCL6) activity.

Provided herein are liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.

This invention relates to the field of tumor molecular biology, specifically providing the application of targeting the ISG15 protein in chemotherapy sensitization drugs and prognostic assessment for B-cell lymphoma. This invention also provides the use of the ISG15 protein as a biomarker in the preparation of prognostic assessment products for B-cell lymphoma. This invention effectively reverses chemotherapy-induced senescence-related drug resistance and restores the chemosensitivity of tumor cells by inhibiting the ISG15 pathway; simultaneously, the ISG15 expression level can serve as a biomarker for prognostic assessment of B-cell lymphoma. This invention provides a new technical solution for overcoming chemotherapy resistance in B-cell lymphoma and assessing patient prognosis.

The invention discloses a method for screening a B-cell lymphoma biomarker, and belongs to the technical field of bioinformatics. The invention aims to provide a more accurate and simple method for screening the B-cell lymphoma biomarker. The invention provides a method for screening a B cell lymphoma biomarker. The relation between the infiltration ratio of all cell subgroups of T / NK and myeloid cells and the lifetime of a patient is screened out by utilizing scRNA-seq data of Burki lymphoma, diffuse large B cell lymphoma, follicular lymphoma and spleen marginal region lymphoma and bulk RNA-seq data of a Burki lymphoma and diffuse large B cell lymphoma database. And a theoretical basis is provided for screening survival analysis of lymphoma diseases.

Provided is a method for diagnosing the prognosis and therapeutic effect for chemotherapy in patients with rheumatoid arthritis-associated lymphoproliferative disorder (RA-LPD), who have developed a lymphoproliferative disorder (LPD) during the treatment of rheumatoid arthritis (RA). This is a kit for diagnosing the prognosis and therapeutic effect for chemotherapy in rheumatic arthritis-associated lymphoproliferative disorder (RA-LPD) patients, who have developed LPD during RA treatment. The kit comprises: means for detecting an inositol 1,4,5-triphosphate receptor (ITPR) type 2 (ITPR2) gene mutation in a biological sample from a patient; and instructions for determining that the prognosis and therapeutic effect for chemotherapy are poor when an ITPR2 gene mutation is present in the biological sample from the patient. The LPD is diffuse large B-cell lymphoma (DLBCL). For the ITPR2 gene mutation, Chr12:rs26744460 is GT or GG. Use for the diagnosis of non-RA lymphoma patients is also possible.

The application discloses a kind of bispecific anti-CD3 / CD20 antibodies and its application in B cell lymphoma, belong to the field of biological medicine technology.The bispecific antibody uses "tandem type" molecular structure, by the single-chain antibody (scFv) of anti-CD20 and the nanometer antibody (VHH) of anti-CD3 are fused by flexible connecting peptide.The high-purity bispecific antibody BsAb-20S3V is obtained by CHO cell stable expression system, and it has nanomolar level affinity to CD20+ and CD3+ cells.Experiments in vitro prove that the antibody can effectively mediate T cell specific killing to Raji cell, and the maximum killing rate can reach 75%-90%.In vivo pharmacodynamic evaluation shows that in tumor-bearing mouse model, high-dose group can significantly inhibit tumor growth and induce tumor negative growth.The antibody has good potential to prepare B cell lymphoma treatment drugs.